DCTH Delcath Systems, Inc.

0.06
0  -2%
Previous Close 0.06
Open 0.06
Price To book 0.00
Market Cap 246720.00
Shares 4,112,000
Volume 7,527,262
Short Ratio 0.24
Av. Daily Volume 10,250,500

SEC filingsSee all SEC filings

  1. PRE 14A - Other preliminary proxy statements 17756314
  2. 8-K - Current report 17732345
  3. 10-K - Annual report (Section 13 and 15(d), not S-K Item 405) 17720289
  4. 8-K - Current report 17678331
  5. 8-K - Current report 17630598

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 ongoing as of November 2016.
Melphalan Hepatic Delivery System (Melphalan HDS)
Hepatocellular carcinoma (HCC) - cancer
Phase 3 initiated February 2016. Ongoing as of November 2016. Interim safety analysis due 2H 2017.
Melphalan Hepatic Delivery System (Melphalan HDS)
Hepatocellular carcinoma (HCC) - cancer
CRL September 13, 2013.
CHEMOSAT system
Unresectable metastatic ocular melanoma in the liver

Latest News

  1. Spire Southampton Hospital in UK Celebrating Over 100 CHEMOSAT Treatments
  2. Delcath Announces 2016 Financial Results
  3. Delcath Clinical Study Design Approved By FDA
  4. Delcath Announces Special Protocol Assessment Agreement With FDA for Pivotal Trial With Melphalan/HDS in Intrahepatic Cholangiocarcinoma
  5. Delcath Systems To Present At ROTH Capital Partners 29th Annual Growth Stock Conference On March 13, 2017
  6. Published Review Shows Delcath Investigational PHP Doubles Overall Survival Over Other Targeted Liver Therapies
  7. Analysis From Two Institutions Shows Strong Tumor Response, Overall Survival Potential of Delcath Investigational PHP Therapy
  8. Delcath Systems to Present at the 2nd Annual Disruptive Growth & Healthcare Conference
  9. Delcath Systems To Present At The NobleCon13 - Noble Capital Markets' Thirteenth Annual Investor Conference On January 31, 2017
  10. New Outcomes Data Using Delcath's Melphalan/HDS To Treat Unresectable Metastatic Ocular Melanoma To The Liver Accepted For Oral Presentation At Regional Cancer Therapies Symposium
  11. Delcath Announces Ongoing Patient Treatment And Data Collection In Intrahepatic Cholangiocarcinoma Study Cohort
  12. DryShips, Merrimack Tumble into Friday’s 52-Week Low Club
  13. Delcath Systems, Inc. :DCTH-US: Earnings Analysis: Q3, 2016 By the Numbers : November 14, 2016
  14. Delcath Issues Letter to Stockholders
  15. Review Of Delcath's CHEMOSAT Accepted For Publication In Advances In Therapy
  16. Delcath Announces New U.S. Clinical Sites For FOCUS Phase 3 Trial For Ocular Melanoma Liver Metastases
  17. Here’s Why These Five Stocks Are on the Move Today
  18. Delcath Prices Underwritten Public Offering of Common Stock and Warrants
  19. Delcath Announces Proposed Public Offering of Common Stock and Warrants
  20. Delcath Sponsors Ocular Melanoma Foundation Patient Retreat

SEC Filings

  1. PRE 14A - Other preliminary proxy statements 17756314
  2. 8-K - Current report 17732345
  3. 10-K - Annual report (Section 13 and 15(d), not S-K Item 405) 17720289
  4. 8-K - Current report 17678331
  5. 8-K - Current report 17630598
  6. 8-K - Current report 17628790
  7. 8-K - Current report 17612958
  8. 8-K - Current report 17612948
  9. SC 13G - Statement of acquisition of beneficial ownership by individuals 17602815
  10. SC 13G/A (Amend) - Statement of acquisition of beneficial ownership by individuals 17575403